On July 24, 2025 Incyte (Nasdaq:INCY) reported that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025, to be held October 17-21 in Berlin (Press release, Incyte, JUL 24, 2025, View Source [SID1234654514]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We’re looking forward to presenting the latest findings across our oncology portfolio at this year’s congress, including initial data for our TGFβR2×PD-1-directed bispecific antibody, INCA33890, and our novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, INCB161734," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "These data underscore the importance of establishing treatment options for advanced solid tumors and speak to the potential of INCA33890 and INCB161734 as personalized therapies to enhance outcomes for patients with cancer across a range of tumor types."
Details on the abstracts accepted for oral presentation at ESMO (Free ESMO Whitepaper) include:
INCB161734 (KRAS G12D)
Preliminary Phase 1 Results Of INCB161734, A Novel Oral KRAS G12D Inhibitor, In Patients With Advanced Or Metastatic Solid Tumors
(Session Title: Proffered paper session: Developmental therapeutics. [October 19, 8:45 – 10:15 a.m. ET [2:45 – 4:15 p.m. CEST]. Abstract #916O.)
INCA33890 (PD-1/TGFβR2)
A Phase 1 Study Of INCA33890, A PD-1/Tgfβr2 Bispecific Antibody, For Advanced Solid Tumours
(Session Title: Mini oral session: Investigational immunotherapy. [October 17, 8:00 – 9:30 a.m. ET [2:00 – 3:30 p.m. CEST]. Abstract #1522.)
INCAGN2385 (LAG-3)
Retifanlimab (Anti–PD-1 Mab) Alone Or In Combination With Anti-LAG3 ± Anti-TIM3 Mabs In Previously Untreated, Recurrent And/Or Metastatic (R/M) PD-L1+ HNSCC: A Double-Blind Randomised Controlled Phase 2 Trial
(Session Title: Mini oral session: Head and neck cancer. [October 19, 10:30 a.m. – 12:00 p.m. ET [4:30 – 6:00 p.m. CEST]. Abstract #1325.)
All regular abstracts accepted for presentation at the ESMO (Free ESMO Whitepaper) Congress 2025 will be published online via the ESMO (Free ESMO Whitepaper) website on Monday, October 13 at 6:05 p.m. ET (12:05 a.m. CEST). All accepted abstracts will be published online in the ESMO (Free ESMO Whitepaper) Congress 2025 Abstract Book, a supplement to the official ESMO (Free ESMO Whitepaper) journal, Annals of Oncology.
More information regarding the 2025 ESMO (Free ESMO Whitepaper) Congress can be found at: View Source